{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:35:12Z","timestamp":1790757312068,"version":"4.1.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"DOI":"10.1093\/ckj\/sfab266","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:27:51Z","timestamp":1639139271000},"page":"831-833","source":"Crossref","is-referenced-by-count":24,"title":["Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor"],"prefix":"10.1093","volume":"15","author":[{"given":"Yasunori","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Miyamoto Hospital, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yokose","sequence":"additional","affiliation":[{"name":"Dialysis Center, Miyamoto Hospital, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Nagata","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Miyamoto Hospital, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Miyamoto Hospital, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"2022033100261489200_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/hepr.12769","article-title":"Treatment for cirrhotic ascites","volume":"47","author":"Kawaratani","year":"2017","journal-title":"Hepatol Res"},{"key":"2022033100261489200_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/1744-9987.12469","article-title":"Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis","volume":"20","author":"Kozaki","year":"2016","journal-title":"Ther Apher Dial"},{"key":"2022033100261489200_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes","volume":"72","author":"Montalvo-Gordon","year":"2020","journal-title":"Hepatology"},{"key":"2022033100261489200_bib4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2022033100261489200_bib5","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2011.09.011","article-title":"Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study","volume":"33","author":"Kasichayanula","year":"2011","journal-title":"Clin Ther"},{"key":"2022033100261489200_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022033100261489200_bib7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfab266\/42903360\/sfab266.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/4\/831\/43057960\/sfab266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/4\/831\/43057960\/sfab266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:26:30Z","timestamp":1648686390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/4\/831\/6460509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,13]]},"published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfab266","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2021,12,13]]}}}